Tag Archives: cancer

Modulight Spotlights: LASER-SHARP RESEARCH – January 2025

January 22, 2025 by Modulight Content
No comments
   Modulight Spotlights: LASER-SHARP RESEARCH – January 2025 We are pleased to highlight this month a new study published in Cancer Immunology, Immunotherapy by Hisataka Kobayashi’s team at National Cancer Institute, NIH. They developed light-activated immunotherapy targeting a specific protein found on the surface of many cancer cells, called tissue factor. This therapy consists of antibody-photoabsorber conjugate that binds to cancer cell surface, and in response to near-infrared light, induces photochemical reaction that results in membrane destruction and immunogenic cell death. When this novel agent was Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – September 2024

September 23, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – September 2024 University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients. Cancer cells have developed various ways to protect themselves from drugs. When several clinically used photoactive drugs were studied, it was shown that some of them were being actively pumped out by cancer cells, thus likely limiting the full therapeutic potential Continue reading →

Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro

September 20, 2024 by Modulight Content
No comments
Published in: Cancer Drug Resistance Authors: Shruti Vig1, Payal Srivastava1,#, Idrisa Rahman1,2,#, Renee Jaranson1, Anika Dasgupta1, Robert Perttilä3, Petteri Uusimaa3, Huang-Chiao Huang1  Published in: Cancer Drug Resistance Authors: Shruti Vig1, Payal Srivastava1,#, Idrisa Rahman1,2,#, Renee Jaranson1, Anika Dasgupta1, Robert Perttilä3, Petteri Uusimaa3, Huang-Chiao Huang1 University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients. Cancer cells have developed various ways to protect themselves from drugs. When several clinically used photoactive drugs were studied, it was shown that some of them were being actively pumped out by cancer cells, thus likely limiting the full therapeutic potential of these Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – July 2024

July 26, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – July 2024 Exciting new findings in prostate cancer research were reported by Xinning Wang and team at Case Western University, Comprehensive Cancer Center. Prostate cancer is the most common cancer among men and despite typically good prognosis, is a leading cause of cancer-related death. In the new study, the team combined chemotherapy with a novel light-activated, theranostic agent to enable targeted imaging and treatment of prostate cancer. Using ML7710 laser at 672 nm for activation of the drug, they were Continue reading →

Ru(II) Oligothienyl Complexes with Fluorinated Ligands: Photophysical, Electrochemical, and Photobiological Properties

May 10, 2024 by Modulight Content
No comments
Published in: Inorganic Chemistry Authors: Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Alisher Talgatov, Gurleen Kaur, Antonio Francés-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland  Published in: Inorganic Chemistry Authors: Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Alisher Talgatov, Gurleen Kaur, Antonio Francés-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland A series of Ru(II) complexes were characterized and assessed for phototherapy effects toward cancer cells. Also activity in hypoxia was evaluated, with some of the compounds retaining partial activity in hypoxia. ML8500 was used for dosimetry studies, assessing impact of irradiance on the phototoxicity of Ru-4T with several different wavelengths. LEDs were used for Continue reading →

Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells

March 14, 2024 by Modulight Content
No comments
Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi  Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi A new method called phototruncation-assisted cell tracking (PACT) can be used to noninvasively track migration of immune cells to understand anti-cancer immunity mechanisms. PACT is based on irreversible photo-induced truncation reaction, transforming Cy7 into Cy5 when exposed to NIR light (780 nm). PACT was used in this study to monitor spatiotemporal migration of immune cells between tumor and Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – December 2023

December 28, 2023 by Modulight Content
No comments
Modulight Spotlights: LASER-SHARP RESEARCH – December 2023 Organic compounds are one of the leading causes of water pollution. Rhodamine 6G is a commonly used dye in the food and textile industries and can cause cancer when consumed in contaminated water. To tackle this problem, Professor T. Nyokong’s team at Rhodes University studied photocatalysis with ML7710 for degrading rhodamine, and showed increased degradation efficiency when photocatalysis was combined with ultrasound (sonocatalysis). This Laser-Sharp study offers a new method for more efficient degradation of organic pollutants for environmental Continue reading →

Laser illumination platform with real-time spectral monitoring and treatment

March 7, 2022 by Modulight Content
No comments
Presented in: SPIE BIOS 2022 Authors: Visa Kaivosoja, Robert Perttilä, Elias Kokko, Timo Tanila, Zoe Ylöniemi, Petteri Uusimaa, Modulight Corporation (Finland)    Presented in: SPIE BIOS 2022 Authors: Visa Kaivosoja, Robert Perttilä, Elias Kokko, Timo Tanila, Zoe Ylöniemi, Petteri Uusimaa, Modulight Corporation (Finland) Personalized medicine is one of the main directions in current cancer care. To support this trend, Modulight has designed a laser illumination platform with real-time spectral monitoring to adjust treatments based on each patient’s optical properties of the tissue, providing more personalization to light-based treatments. The laser has been designed to illuminate and retrieve spectral data from the tumor tissue simultaneously from up to Continue reading →

Light delivery optimization for H&N cancer treatment

August 30, 2021 by Modulight Content
No comments
Results Illumination with one fiber Some level of tissue heating was observed at all used light intensities. At lower intensities (60-100 mW/cm), less than 5% of the tumor was subjected to >60 ⁰C temperature, a point where irreversible thermal damage will immediately occur (photothermal ablation). At intensities of 150-200 mW/cm, 15-20% of the tumor was at >60 ⁰C temperature. At 400 mW/cm, which is FDA-recommended light irradiance for iPDT, a substantial portion of the tumor, up to 60%, was above 60 ⁰C.   Above figures Continue reading →Customer case Roswell Park Comprehensive Cancer Center was founded in 1898 as the first institute in the US devoted exclusively to cancer treatment and research. It is also the place where photodynamic therapy (PDT) was developed in the late 1970s by Thomas Dougherty. The PDT center at Roswell Park is a leader in the use of photodynamic therapy for treating different cancers. Research work includes treatment planning and light dosimetry for interstitial and intraoperative PDT to improve the quality of life and survival of cancer patients Continue reading →

Protected: Vision-sparing targeted phototherapy for uveal melanoma

July 30, 2021 by Modulight Content
No comments
There is no excerpt because this is a protected post.Customer case Aura Biosciences, headquartered in Cambridge, MA, is developing a new class of photoactivated therapy for cancer patients together with National Cancer Institute, Emory Eye Center and Wills Eye Hospital. The therapy is based on virus-like conjugates and its primary indication is uveal melanoma. The goal is to eventually develop this technology for multiple cancer indications, such as non-muscle invasive bladder cancer (NMIBC), for which plans are underway to conduct a clinical trial. Dr. Carol Shields, MD – Aura Biosciences Dr. Rhonda Kines, PhD – Continue reading →